Aller au contenu principal
Accès ouvert déclaré 2025 article

Serum metabolomics in pulmonary sarcoidosis: metabolic signatures across prognoses

3Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Sarcoidosis is a systemic inflammatory disease, primarily affecting the lungs, with a prognosis that varies widely among patients. While some patients recover spontaneously after diagnosis, others experience disease progression. Currently, the metabolomic profile associated with pulmonary sarcoidosis and its different clinical outcomes remains poorly understood. Serum samples from 29 pulmonary sarcoidosis patients and 10 healthy controls were analyzed using untargeted UPLC-MS/MS metabolomics. Univariate and multivariate analyses identified differentially expressed metabolites, followed by pathway enrichment to evaluate their biological relevance. Patients were further stratified into self-healing ( n = 11) and progressive ( n = 18) subgroups based on prognosis. Differential metabolites between subgroups were compared, potential biomarkers were selected, and their diagnostic performance assessed. Correlations with clinical parameters were also analyzed to explore associations with disease progression. Sarcoidosis patients showed distinct serum metabolic profiles compared to healthy controls, with 10 upregulated and 199 downregulated metabolites. Pathway analysis indicated enrichment in amino acid, lipid, and immune-related pathways. Between prognostic subgroups, 25 differential metabolites were identified. Uric acid, testosterone sulfate, allopregnanolone sulfate, and 24,25-dihydroxyvitamin D 3 emerged as key metabolites with prognostic value and moderate correlations with clinical parameters. This study highlights distinct serum metabolic profiles associated with sarcoidosis prognosis, suggesting that specific metabolic alterations may aid in monitoring and predicting disease outcomes. These findings offer a foundation for future research into personalized treatment and management strategies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Serum metabolomics in pulmonary sarcoidosis: metabolic signatures across prognoses
Date Crossref
02/08/2025
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Sarcoidosis and Beryllium Toxicity ResearchMetabolomics and Mass Spectrometry StudiesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.